Aleksandra Nasiek

Ms. Aleksandra Nasiek


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Case Reports in Oncology
Verified
Journal Article
Open access
PPPaweł Polanowski
Paweł Polanowski
MHMarlena Howorus
Marlena Howorus
ANAleksandra Nasiek
Aleksandra Nasiek
AKAnna Kozub
Anna Kozub
APAgnieszka Pietruszka
Agnieszka Pietruszka
KSKrzysztof Składowski
Krzysztof Składowski
Introduction: Recurrent oral squamous cell carcinoma (SCC) poses significant challenges in treatment, requiring a multifaceted approach for effective management. Case Presentation: We present the case of a 68-year-old patient with a history of keratonizing SCC of the mandibular gingiva, treated with surgical resection, adjuvant radiotherapy (RT) to a total dose of 60 Gy in 30 fractions and 6 cycles of concurrent chemotherapy. After 6 years of follow-up, the patient experienced a local late recurrence in clinical stage rT4N0M0 requiring palliative chemotherapy (6 cycles of PF regimen). Due to progression, nivolumab-based immunotherapy was administered. After the 11th cycle of immunotherapy, high-dose re-irradiation (18 Gy in 3 fractions) was applied due to subsequent progression. The addition of stereotactic RT to the immunotherapy allowed nivolumab to be continued until cycle 64, ensuring long-term disease stabilization with acceptable tolerability. Consecutive palliative chemotherapy included paclitaxel and methotrexate. Conclusion: This case highlights the complex management of recurrent oral SCC, emphasizing the role of combining stereotactic RT with nivolumab in prolonging the administration of immunotherapy.

21 October 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AKAnna Kozub
Anna Kozub
ANAleksandra Nasiek
Aleksandra Nasiek
NBNatalia Bohun
Natalia Bohun
MBMartyna Bednarczyk
Martyna Bednarczyk
ŁSŁukasz Sędek
Łukasz Sędek
SGSebastian Grosicki
Sebastian Grosicki
Background and Clinical Significance : Waldenström macroglobulinemia (WM) is a rare, indolent B-cell non-Hodgkin lymphoma, characterised by the presence of monoclonal immunoglobulin M (IgM) and lymphoplasmacytic infiltration of the bone marrow. It is often associated with various haematological and systemic disorders, including previous cold agglutinin disease (CAD), a condition where cold-sensitive antibodies lead to haemolysis. Case Presentation: A 55-year-old male patient was admitted to the Internal Diseases Ward with symptoms of weakness, reduced effort tolerance, and weight loss, along with life-threatening normoblastic anaemia (haemoglobin [Hb]: 3.90 g/dL). Initial blood tests raised suspicion of CAD due to the presence of multiple blood clots, as well as a decrease in lymphocyte and neutrophil counts. CAD was then confirmed by a cold agglutinin titre of 1:2000 and direct antiglobulin test ([DAT] 4+). Two weeks later, upon transfer to the Haematological Diseases Ward, further investigation revealed elevated IgM levels (up to 31.55 g/L). Additional diagnostic tests, including serum protein electrophoresis, imaging, multiparametric flow cytometry, and bone marrow biopsy, confirmed the diagnosis of WM. The L265P MYD88 mutation test was positive. Treatment with intravenous rituximab was initiated, followed by bendamustine/rituximab (BR) therapy protocol as first-line treatment. After two cycles, the patient’s clinical condition and laboratory results significantly improved, with a marked reduction in IgM (<0.4 g/L). Hb levels steadily rose to 12.60 g/dL, eliminating the need for further blood transfusions. Conclusions: This case highlights the importance of recognising the coexistence of CAD and WM, which may present with overlapping clinical features, including life-threatening anaemia. Extensive diagnostics and prompt treatment with combination therapy can lead to effective clinical improvement.

23 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
PPPaweł Polanowski
Paweł Polanowski
ANAleksandra Nasiek
Aleksandra Nasiek
AGAleksandra Grządziel
Aleksandra Grządziel
APAgnieszka Pietruszka
Agnieszka Pietruszka
KSKrzysztof Składowski
Krzysztof Składowski
KPKatarzyna Polanowska
Katarzyna Polanowska
Squamous cell carcinoma (SCC) of the larynx in advanced stages is a challenging malignancy to treat with a high recurrence and death rate. An individualized approach to treatment is crucial in such patients. We present a 58-year-old male patient with SCC of the larynx in the T3N0M0 stage who was treated with concurrent radiochemotherapy. A total of 17 months after the radical treatment, the patient underwent a laryngectomy due to recurrence. A total of 11 months after the operation, local failure was diagnosed. In the next order, the patient received six cycles of palliative chemotherapy according to cisplatin 100 mg/m2 and 5-fluorouracil 1000 mg/m2. After three months, due to progression, Nivolumab-based immunotherapy was administered, ensuring disease stabilization. After the 56th cycle of Nivolumab, another progression was documented. The addition of stereotactic radiotherapy (18 Gy in three fractions) to immunotherapy led to significant regression of the disease and enabled the continuation of Nivolumab to the 70th cycle. The presented case demonstrates the usefulness of the combination of stereotactic radiotherapy with immunotherapy in prolonging the local control.

29 August 2025 in Archiv Euromedica
Verified
Journal Article
Closed access
NSNatalia Stefanik
Natalia Stefanik
BLBarbara Lipka
Barbara Lipka
ANAleksandra Nasiek
Aleksandra Nasiek
ZSZofia Stefanik
Zofia Stefanik
JMJulia Maślanka
Julia Maślanka
RWRafał Wiench
Rafał Wiench
Background: Oral squamous cell carcinoma (OSCC) remains a significant global health concern, with high morbidity and mortality largely attributable to delayed diagnosis. Despite the accessibility of the oral cavity for clinical inspection and the presence of well-established risk factors, a considerable proportion of cases are still identified at advanced stages. This report presents a case of rapid tumor progression in a patient without classical risk factors. Case Presentation: A 44-year-old male with no history of tobacco or alcohol use, systemic illness, or familial cancer, presented with a lateral tongue ulcer attributed to trauma. Clinical examination revealed a 10 x 14 mm lesion. Biopsy was initially postponed due to lack of consent, and conservative treatment was administered. Temporary improvement was observed. However, within 20 days, the lesion markedly enlarged. Urgent biopsy confirmed moderately differentiated OSCC. The tumor was staged as T4N0M0 according to AJCC 8th edition. The patient underwent hemiglossectomy, bilateral neck dissection, and adjuvant radiochemotherapy. Although remission was achieved, the patient died of pneumonia one week after completing treatment. Conclusions: This case highlights the potential for rapid OSCC progression in low-risk individuals and emphasizes the need for immediate diagnostic action in the presence of suspicious oral lesions. Conventional oral examination must be followed by biopsy when malignancy is suspected. Early multidisciplinary collaboration and clear patient communication are essential to avoid preventable delays and improve clinical outcomes.

29 August 2025 in Archiv Euromedica
Verified
Journal Article
Closed access
BLBarbara Lipka
Barbara Lipka
JFJakub Fiegler-Rudol
Jakub Fiegler-Rudol
ANAleksandra Nasiek
Aleksandra Nasiek
MLMichał Lipka
Michał Lipka
MPMichał Piotrowski
Michał Piotrowski
RWRafał Wiench
Rafał Wiench
Aim: This narrative review critically examines the clinical and mechanistic evidence regarding the use of omega-3 polyunsaturated fatty acids (PUFAs) as adjuncts in periodontal therapy. The objective is to assess the consistency of reported outcomes, evaluate the quality of available randomized controlled trials (RCTs), and identify methodological limitations that hinder firm clinical recommendations. Methods: A structured literature search was conducted in PubMed, Scopus, and Embase for peer-reviewed studies published between January 2010 and April 2025. Search terms included “omega-3 fatty acids”, “PUFA”, “EPA”, “DHA”, “periodontitis”, “host modulation”, and related terms. Inclusion criteria comprised clinical trials, systematic reviews, and relevant experimental studies with full-text availability. No meta-analysis was performed due to heterogeneity in study design and outcomes. Results: Omega-3 fatty acids, particularly EPA and DHA, may contribute to periodontal therapy by modulating inflammation, enhancing the production of specialized pro-resolving mediators (SPMs), and reducing levels of pro-inflammatory cytokines. Some RCTs report improvements in probing pocket depth (PPD), clinical attachment level (CAL), and salivary biomarkers when omega-3s are used adjunctively with scaling and root planing (SRP). However, variability in dosage, source, treatment duration, and outcome measures limits comparability. Few studies assessed SPM levels or reported effect sizes and confidence intervals. Evidence on co-administration with low-dose acetylsalicylic acid (ASA) is inconclusive. Conclusions: Although mechanistically plausible and supported by selected clinical trials, the adjunctive use of omega-3 fatty acids in periodontitis lacks sufficient high-quality, consistent evidence to justify clinical recommendations. Standardized RCTs with robust design, biochemical monitoring, and long-term follow-up are needed. Omega-3s remain a promising component of integrative care but should not yet replace established therapeutic protocols.

29 April 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
ANAleksandra Nasiek
Aleksandra Nasiek
PPPaweł Polanowski
Paweł Polanowski
MHMarek Hamm
Marek Hamm
AKAnna Kozub
Anna Kozub
BLBarbara Lipka
Barbara Lipka
KSKrzysztof Składowski
Krzysztof Składowski
Background: Synchronous cancers, defined as malignancies diagnosed concurrently or within 2 months of each other, are rare, with an incidence of 1%–6%. Environmental factors such as tobacco smoking play a significant role in their development. Patients with head and neck squamous cell carcinoma (SCC) are at increased risk of second malignancies, complicating treatment strategies and prognosis. This report presents a rare case of synchronous SCC of the lower lip and papillary thyroid carcinoma (PTC). Case: A 61‐year‐old male with a history of smoking presented with a 2.5 cm exophytic lesion of the lower lip, diagnosed as keratinizing SCC. A suspicious cervical lymph node was revealed, which intraoperatively demonstrated metastatic PTC. Following partial lip resection and neck dissection, total thyroidectomy was performed, confirming a 1.5 mm PTC focus with micrometastases. The patient underwent adjuvant conventional radiotherapy (RTH) for SCC (66 Gy in 33 fractions) and radioiodine therapy (131‐I) for PTC. Post‐therapeutic scintigraphy identified suspected micrometastases in the iliac bone, prompting further 131‐I treatment. Following completion of therapy, the patient achieved a complete response, with no radiologic or clinical evidence of residual disease from both malignancies. Conclusion: Synchronous SCC of the lip and PTC are exceedingly rare, lacking standardized treatment guidelines. This case highlights the necessity of a multidisciplinary approach, integrating surgery, RTH, and systemic therapy. Careful postoperative histopathological assessment of lymph nodes may reveal unexpected findings that necessitate further diagnostic work‐up and a multidisciplinary approach, as this can significantly influence staging, treatment decisions, and patient prognosis, representing an important key learning point.